Evidence map›Paper›PMID 32278976›Full record

ArticleNeuropharmacology2020

NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice.

Katarzyna M Targowska-Duda, Akihiko Ozawa, Zachariah Bertels, Andrea Cippitelli, Jason L Marcus, Hanna K Mielke-Maday, Gilles Zribi, Amanda N Rainey, Brigitte L Kieffer, Amynah A Pradhan and 1 more

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Ro 64-6198, a selective NOP receptor agonist attenuates social impairments associated with NTG-induced migraine pain.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Rare GPR37L1 Variants Reveal Potential Association between GPR37L1 and Disorders of Anxiety and Migraine.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Katarzyna M Targowska-DudaDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States; Department of Biopharmacy, Medical University of Lublin, Lublin, Poland.
Akihiko OzawaDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States.
Zachariah BertelsDepartment of Psychiatry, University of Illinois at Chicago, Chicago, IL, United States.
Andrea CippitelliDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States.
Jason L MarcusDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States.
Hanna K Mielke-MadayDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States.
Gilles ZribiDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States.
Amanda N RaineyDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States.
Brigitte L KiefferDouglas Hospital Research Center, Dep. of Psychiatry, School of Medicine, McGill University, Montreal, Quebec, Canada; INSERM U1114, Strasbourg, France.
Amynah A PradhanDepartment of Psychiatry, University of Illinois at Chicago, Chicago, IL, United States.
Lawrence TollDepartment of Biomedical Science, Florida Atlantic University, Boca Raton, FL, United States. Electronic address: ltoll@health.fau.edu.
Florida Atlantic University · USUniversity of Illinois Chicago · USDouglas Mental Health University Institute · CAMedical University of Lublin · PL

Funding

MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIAR01DA023281 · NIDA · TORREY PINES INST FOR MOLECULAR STUDIES · PI TOLL, LAWRENCE R · 2007 to 2021
$6.4M
The role of delta opioid receptors in trigeminovascular painR01DA040688 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PRADHAN, AMYNAH AMIR ALI · 2016 to 2020
$1.8M
NIDA NIH HHS R01 DA023281NIDA NIH HHS R01 DA040688
6 · The paper itself

Abstract

Migraine is an extraordinarily prevalent and disabling headache disorder that affects one billion people worldwide. Throbbing pain is one of several migraine symptoms including sensitivity to light (photophobia), sometimes to sounds, smell and touch. The basic mechanisms underlying migraine remain inadequately understood, and current treatments (with triptans being the primary standard of care) are not well tolerated by some patients. NOP (Nociceptin OPioid) receptors, the fourth member of the opioid receptor family, are expressed in the brain and periphery with particularly high expression known to be in trigeminal ganglia (TG). The aim of our study was to further explore the involvement of the NOP receptor system in migraine. To this end, we used immunohistochemistry to examine NOP receptor distribution in TG and trigeminal nucleus caudalus (TNC) in mice, including colocalization with specific cellular markers, and used nitroglycerin (NTG) models of migraine to assess the influence of the selective NOP receptor agonist, Ro 64-6198, on NTG-induced pain (sensitivity of paw and head using von Frey filaments) and photophobia in mice. Our immunohistochemical studies with NOP-eGFP knock-in mice indicate that NOP receptors are on the majority of neurons in the TG and are also very highly expressed in the TNC. In addition, Ro 64-6198 can dose dependently block NTG-induced paw and head allodynia, an effect that is blocked by the NOP antagonist, SB-612111. Moreover, Ro 64-6198, can decrease NTG-induced light sensitivity in mice. These results suggest that NOP receptor agonists should be futher explored as treatment for migraine symptoms. This article is part of the special issue on Neuropeptides.

Indexed as

AnimalsDose-Response Relationship, DrugFemaleImidazolesMaleMiceMice, Inbred C57BLMice, TransgenicMigraine DisordersNitroglycerinNociceptin ReceptorReceptors, OpioidSpiro CompoundsTrigeminal NucleiImidazolesNitroglycerinNociceptin ReceptorOprl1 protein, mouseReceptors, OpioidRo 64-6198Spiro CompoundsCephalic painGlyceryl trinitrateNitroglycerineNOP receptorRo 64-6198Trigeminal ganglia

Identifiers

PMID32278976
PMCPMC7243257
OpenAlexW3009379150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.